Biopharma firm Cytokinetics Q2 revenue jumps

Cytokinetics, Incorporated

07/08/2025 21:13

Overview

Cytokinetics Q2 revenue rises to $66.8 mln, driven by collaboration with Bayer

Net loss narrows to $134.4 mln despite increased R&D and G&A expenses

Company focuses on aficamten's FDA approval and commercialization by early 2026

Outlook

Cytokinetics maintains 2025 GAAP operating expense guidance at $670-$710 mln

Company plans commercial launch of aficamten in early 2026

Result Drivers

BAYER COLLABORATION - Revenue boost from collaboration with Bayer for aficamten in Japan

REGULATORY PROGRESS - Advancements in regulatory reviews for aficamten in U.S., E.U., and China

COMMERCIAL READINESS - Expanded U.S. and European commercial activities for potential aficamten launch

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 R&D Revenue
$2.42 mln
Q2 EPS
-$1.12
Q2 Net Income
-$134.37 mln
Q2 Basic EPS
-$1.12
Q2 Operating Expenses
$178.28 mln
Q2 Operating Income
-$111.51 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cytokinetics Inc is $70.00, about 49.8% above its August 6 closing price of $35.14

Press Release: ID:nGNX9NdW09

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)